Sanaz Memarzadeh MD PhD

Gynecologic Oncology

Professor, Gynecologic Oncologist Obstetrics & Gynecology, UCLA School of Medicine Director of the G.O. Discovery Laboratory

Summary

Sanaz Memarzadeh, MD PhD, is a surgeon-scientist based in Los Angeles, CA, with a subspecialty in Gynecologic Oncology. She completed her fellowship in Gynecologic Oncology and residency in Obstetrics and Gynecology at the UCLA David Geffen School of Medicine/UCLA Medical Center. Dr. Memarzadeh holds a medical degree from the University of Pittsburgh School of Medicine and a Ph.D. in Molecular Biology from UCLA. Her expertise includes minimally invasive surgery and cancers such as ovarian, cervical, and vulvar cancer, as well as robotic surgery. She is an NIH funded investigator and has contributed to basic translational and clinical research, conducting trials on treatments for advanced ovarian cancer, and has an extensive publication record in respected journals. Her work has been recognized with several honors, including being named among Southern California's Super Doctors and Los Angeles Top Doctors.

University of California Los AngelesPh.D., Molecular Biology, 2003 - 2008
UCLA David Geffen School of Medicine/UCLA Medical CenterFellowship, Gynecologic Oncology, 2000 - 2003
UCLA David Geffen School of Medicine/UCLA Medical CenterResidency, Obstetrics and Gynecology, 1996 - 2000
University of Pittsburgh School of MedicineClass of 1996

Super Doctors of Southern California Super Doctors, 2020-2024
UCLA STAR Program Distinguished Alumni UCLA, 2023
Los Angeles Top Doctors Top Doctors, 2018, 2020-2023
Alpha omega alpha
Los Angeles City Council recognition for commitment to ovarian cancer research Los Angeles City Council, 2017
APGO Excellence in Teaching Award APGO, 2014
CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013
Most Compassionate Doctor American Registry
Join now to see all

PubMed

Commentary: Ovarian Cancer: Path to Effective Treatments.
Anahid Jewett, Sanaz Memarzadeh, Kawaljit Kaur
Critical Reviews in Immunology. 2025-01-01
PGC-1α drives small cell neuroendocrine cancer progression toward an ASCL1-expressing subtype with increased mitochondrial capacity.
Grigor Varuzhanyan, Chia-Chun Chen, Jack Freeland, Tian He, Wendy Tran
Proceedings of the National Academy of Sciences of the United States of America. 2024-12-03
2 citations
Exploring the Potential of Natural Killer Cell-Based Immunotherapy in Targeting High-Grade Serous Ovarian Carcinomas.
Kawaljit Kaur, Jashan Sanghu, Sanaz Memarzadeh, Anahid Jewett
Vaccines. 2024-06-18

Lectures

Below the Belt Gynecologic Cancers: Underfunded and Understudied
World Molecular Imaging Society 2024 - 9/10/2024
Tackling the challenge of carcinosarcomas arising from the mullerian duct
UCLA Pharmacology Lecture - 6/6/2024
Devising strategies for targeting platinum resistant ovarian cancer
Parker Institute for Cancer Immunotherapy - 9/8/2023
Gynecology Case Review with an Emphasis on Clinical Significance; A discussion between a pathologist and a gynecology oncology surgeon
Los Angeles Society of Pathologists - 3/14/2023
Impact of Genetics on Personalizing Treatment of Gynecologic Cancers
9/5/2019
Overcoming Mechanisms of Therapy Resistance in Gynecologic Cancers
CADE Workshop, Washington DC - 7/29/2019
What are the signs of ovarian cancer?
UCLA - 9/25/2018
Ovarian Cancer: What You Need to Know
UCLA - 9/20/2018
Ovarian Cancer: Standard of Care and Beyond
UCLA - 5/1/2018
Join now to see all

Other

Uterine sarcoma: Classification, clinical manifestations, and diagnosis
Memarzadeh S, Mundt AJ, Berek JS
http://www.uptodate.com/contents/uterine-sarcoma-classification-clinical-manifestations-and-diagnosi
UpToDate, Wolters Kluwer Health - 2013-04-10

UCLA Researchers Unite to Develop Immunotherapy They Hope Will Transform Ovarian Cancer TreatmentMarch 5th, 2025
UCLA Scientists Receive $17.4 Million in CIRM Grants to Advance Novel Stem-Cell Based TreatmentsMay 30th, 2024
Common Causes of Sudden, Unexplained Weight GainSeptember 24th, 2020
Join now to see all

Targeting alternative isoform variation for TCR discovery in platinum-resistant ovarian cancerUNIVERSITY OF CALIFORNIA LOS ANGELES2024–2029
Exploring super charged NK cells as a novel cell-based immune therapy in targeting platinum resistant ovarian cancersVA GREATER LOS ANGELES HEALTHCARE SYSTEM2024–2028
Exploring super charged NK cells as a novel cell-based immune therapy in targeting platinum resistant ovarian cancersVA GREATER LOS ANGELES HEALTHCARE SYSTEM2024–2028
BCCMA: Overcoming chemoresistance in ovarian cancer: Targeting Unique Vulnerabilities in Neuroendocrine-like Ovarian Cancer CellsVA GREATER LOS ANGELES HEALTHCARE SYSTEM2023–2027
BCCMA: Overcoming chemoresistance in ovarian cancer: Targeting Unique Vulnerabilities in Neuroendocrine-like Ovarian Cancer CellsVA GREATER LOS ANGELES HEALTHCARE SYSTEM2023–2027

Member, NRG Developmental Therapeutic committee 2016 - 2025
Member, National Institute of Health, Mechanisms of Cancer Therapeutics A Study Section

UCLA profilehttp://www.uclahealth.org/SanazMemarzadeh
GO Discovery Labhttps://www.godiscoverylab.com
Jonsson Comprehensive Cancer Centerhttps://cancer.ucla.edu/research/find-become-a-member/member-directory?id=417